{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-044876","form_type":"8-K","ticker":"WVE","cik":"0001631574","company_name":"Wave Life Sciences Ltd.","filed_at":"2025-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.245165+00:00","generated_at":"2026-05-25T14:06:36.708105+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Wave Life Sciences Q4 net income $29.3M; cash $302M; obesity and AATD data expected in 2025","bullets":["Q4 2024 revenue $83.7M (up from $29.1M YoY); net income $29.3M vs prior year net loss $16.3M.","Full year 2024 net loss $97.0M, compared to $57.5M in 2023; R&D expenses increased to $159.7M.","Cash $302.1M as of Dec 31, 2024, expected operating runway into 2027; excludes potential GSK milestones.","Dosing underway in INLIGHT trial of WVE-007 in obesity; clinical data expected 2H 2025.","On track to deliver FORWARD-53 48-week DMD data and FDA feedback on accelerated approval in 1Q 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-044876","json":"https://secwatch.observer/filing/0001193125-25-044876.json","markdown":"https://secwatch.observer/filing/0001193125-25-044876.md","text":"https://secwatch.observer/filing/0001193125-25-044876.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1631574/000119312525044876/0001193125-25-044876-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1631574/000119312525044876/d785711d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T14:06:36.708105+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}